Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation ...Middle East

Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for children Data reinforce well-established safety profile of Dupixent TARRYTOWN, N.Y. and PARIS, April 7, 2022 /PRNewswire/ --...

Hence then, the article about dupixent dupilumab approved by european commission for children aged 6 to 11 years with severe asthma with type 2 inflammation was published today ( Thursday 07/04/2022 - 08:21 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation )

Also on site :

• Gwyneth Paltrow’s surprisingly racy Oscars 2026 dress is slit all the way up the sides
• TIER IV unveils AI-based Level 4 autonomous driving, accelerating global platform expansion across Japan, U.S. and Europe
• Conan O’Brien Starts Oscars by Roasting Timothée Chalamet’s Ballet and Opera Controversy as Camera Cuts to ‘Marty Supreme’ Star Laughing